Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate
about
Recent advances in the understanding of antibiotic resistance in Clostridium difficile infectionRecurrent Clostridium difficile infections: the importance of the intestinal microbiotaThe potential for emerging therapeutic options for Clostridium difficile infectionAntimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile InfectionConventional and alternative treatment approaches for Clostridium difficile infectionPreclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pyloriAction of nitroheterocyclic drugs against Clostridium difficile.A filtration based technique for simultaneous SEM and TEM sample preparation for the rapid detection of pathogens.Prevalence of antimicrobial use in a network of Canadian hospitals in 2002 and 2009.Metronidazole-triazole conjugates: activity against Clostridium difficile and parasitesClostridium difficile drug pipeline: challenges in discovery and development of new agentsThe SOS Response Master Regulator LexA Is Associated with Sporulation, Motility and Biofilm Formation in Clostridium difficile.Proteomic analysis of a NAP1 Clostridium difficile clinical isolate resistant to metronidazole.Therapy of Clostridium difficile infection: perspectives on a changing paradigm.Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.Crystal structures of two nitroreductases from hypervirulent Clostridium difficile and functionally related interactions with the antibiotic metronidazole.Multidisciplinary analysis of a nontoxigenic Clostridium difficile strain with stable resistance to metronidazole.Characterization of the impact of rpoB mutations on the in vitro and in vivo competitive fitness of Clostridium difficile and susceptibility to fidaxomicin.Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms.
P2860
Q26767079-FA4944E6-DA85-4B85-BE72-31C33969D9C7Q27023219-900650C6-848C-459B-A381-A754A7366AE8Q28082059-0124CE58-6081-448C-903A-5F65A21A11C5Q28084026-6C2A121A-4CEA-470F-A61A-B64A70C45283Q30235278-2C0AEFBE-ED89-432B-AC7B-7A8244F6110DQ30408277-3100E5D0-0FD3-4DCE-A38B-575F35AF81B4Q34276271-E2217649-574F-4E80-B821-BD6E1E66D5B6Q34303578-0215B190-BC37-4D94-988D-315376AD12F6Q35569879-683F71FA-5767-4535-B2EA-375E36614BACQ35676340-B4D61C2A-5526-433E-B341-48BF11B28F97Q35846436-6D39DC45-494D-4E03-97F7-18971B5133A0Q35872877-EA8504BF-1D4B-4BD0-8426-15B6CF9DB8ECQ37439161-2E187B6F-EFD1-4628-B47E-90EFC3EF527BQ38139991-C4C44B84-6850-4C9F-AB19-8D6173F55F48Q39238893-C54522DE-C908-4949-9A6A-E2F66A23D7D3Q40488232-473282C2-9805-45C6-90B7-FE5F70C4C5C7Q42211317-17ADF73D-AA9C-499C-94A8-2B61989DD28BQ47174281-609D6C4C-C670-46E0-98FC-BDBC5A88314CQ50097140-173CA09A-4983-4D58-AB4E-453B5215A1E1
P2860
Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Characterization of a stable, ...... ium difficile clinical isolate
@ast
Characterization of a stable, ...... ium difficile clinical isolate
@en
Characterization of a stable, ...... ium difficile clinical isolate
@nl
type
label
Characterization of a stable, ...... ium difficile clinical isolate
@ast
Characterization of a stable, ...... ium difficile clinical isolate
@en
Characterization of a stable, ...... ium difficile clinical isolate
@nl
prefLabel
Characterization of a stable, ...... ium difficile clinical isolate
@ast
Characterization of a stable, ...... ium difficile clinical isolate
@en
Characterization of a stable, ...... ium difficile clinical isolate
@nl
P2093
P2860
P1433
P1476
Characterization of a stable, ...... ium difficile clinical isolate
@en
P2093
Canadian Nosocomial Infection Surveillance Program (CNISP)
Daniel R Beniac
Denise Gravel
Jason Zhang
Mark Miller
Michael R Mulvey
Morag R Graham
Pamela Kibsey
Patrick Chong
Romeo Hizon
P2860
P304
P356
10.1371/JOURNAL.PONE.0053757
P407
P577
2013-01-17T00:00:00Z